BAF60c and abdominal aortic aneurysm

BAF60c 和腹主动脉瘤

基本信息

  • 批准号:
    10650179
  • 负责人:
  • 金额:
    $ 54.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Abdominal Aortic Aneurysm (AAA) is a primary medical concern due to the increasing prevalence and high mortality rate upon rupture. Although vascular inflammation, extracellular matrix (ECM) degradation, and subsequent vascular smooth muscle cells (VSMCs) apoptosis are pathologic features and drivers of AAA, efforts to manipulate these processes did not yet result in any effective drug therapies beyond primary prevention, creating an urgent need for new drug-based therapeutic strategies. This will be facilitated by a deeper and comprehensive understanding of the molecular and cellular mechanisms driving onset, progression, and outcomes of AAA. Chromatin remodeling altering gene expression has been linked to most pathophysiologic conditions, including atherosclerosis and diabetes, but its role in AAA remains largely unknown. The BAF60 family comprises three mutually exclusive subunits of the SWItch/Sucrose Non- Fermentable (SWI/SNF) chromatin remodeling complex. Of relevance to the cardiovascular field, they play essential roles in controlling lipid homeostasis, energy metabolism (BAF60a), granulocyte (BAF60b) and heart (BAF60c) development. We found that BAF60a, b and c are differentially expressed in human and mouse AAA tissues, suggesting a potential role of the BAF60 subunits in VSMC biology and the development of AAA. We recently reported that loss of BAF60a in VSMCs prevents experimental AAA by reducing vascular inflammation and ECM degradation in mice. Remarkably, BAF60c is the most abundant BAF60 subunit expressed in VSMC. Our preliminary data show that BAF60c is downregulated in the abdominal aortic aneurysmal tissue in both humans and mice. VSMC BAF60c knockout significantly aggravates elastase-induced AAA, and knockdown of BAF60c in human aortic smooth muscle cells reduced the SMC contractile protein expression and increased inflammatory genes and MMP9 expression. We hypothesize that VSMC-specific BAF60c attenuates AAA development by maintaining the VSMC contractile phenotype, and inhibiting vascular inflammation and ECM degradation. Using gain- and loss-of-function in HASMCs in vitro, AAA-relevant stimuli, our unique VSMC- specific BAF60c knockout and transgenic mice, two established murine AAA models in vivo, and an integrated workflow, we will (Aim 1) Demonstrate that VSMC-specific BAF60c attenuates AAA formation with attention to altered cellular profiles and intercellular cross-talk by scRNAseq and provide proof-of-concept for therapeutic targeting and (Aim 2) Determine the protective mechanisms of BAF60c in VSMC homeostasis in vitro using relevant stimuli and RNAseq, ChIP-seq and co-immunoprecipitation. This work will provide unique mechanistic insights on how various and varying risk factors translate into VSMC dysfunction leading to AAA and provide the basis for developing novel therapies for AAA.
项目概要/摘要 腹主动脉瘤 (AAA) 是一个主要的医学问题,因为其患病率不断增加且发病率高 破裂时的死亡率。尽管血管炎症、细胞外基质(ECM)降解和 随后的血管平滑肌细胞 (VSMC) 凋亡是 AAA 的病理特征和驱动因素, 操纵这些过程的努力尚未导致除了初级疗法之外的任何有效的药物疗法 预防,迫切需要新的基于药物的治疗策略。这将通过一个 对驱动发病的分子和细胞机制有更深入和全面的了解, AAA 的进展和结果。染色质重塑改变基因表达与大多数 病理生理状况,包括动脉粥样硬化和糖尿病,但其在 AAA 中的作用仍然很大程度上 未知。 BAF60家族包括三个互斥的开关/蔗糖非-亚基 可发酵 (SWI/SNF) 染色质重塑复合物。与心血管领域相关,他们发挥 在控制脂质稳态、能量代谢 (BAF60a)、粒细胞 (BAF60b) 和心脏方面发挥重要作用 (BAF60c)开发。我们发现 BAF60a、b 和 c 在人和小鼠 AAA 中差异表达 组织,表明 BAF60 亚基在 VSMC 生物学和 AAA 发展中的潜在作用。我们 最近报道,VSMC 中 BAF60a 的缺失可通过减少血管炎症来预防实验性 AAA 和小鼠 ECM 降解。值得注意的是,BAF60c 是 VSMC 中表达最丰富的 BAF60 亚基。 我们的初步数据表明,BAF60c 在腹主动脉瘤组织中下调 人类和老鼠。 VSMC BAF60c 敲除显着加重弹性蛋白酶诱导的 AAA,并且敲除 人主动脉平滑肌细胞中的 BAF60c 降低 SMC 收缩蛋白表达并增加 炎症基因和 MMP9 表达。我们假设 VSMC 特异性 BAF60c 减弱 AAA 通过维持 VSMC 收缩表型、抑制血管炎症和 ECM 来促进发育 降解。利用体外 HASMC 的功能获得和丧失、AAA 相关刺激,我们独特的 VSMC- 特定的 BAF60c 敲除和转基因小鼠,两个已建立的体内小鼠 AAA 模型,以及一个集成的 工作流程中,我们将(目标 1)证明 VSMC 特异性 BAF60c 会减弱 AAA 形成,并注意 通过 scRNAseq 改变细胞特征和细胞间串扰,并为治疗提供概念验证 靶向和(目标 2)确定 BAF60c 在体外 VSMC 稳态中的保护机制 相关刺激和 RNAseq、ChIP-seq 和免疫共沉淀。这项工作将提供独特的机制 关于各种不同的风险因素如何转化为导致 AAA 的 VSMC 功能障碍的见解,并提供 开发 AAA 新疗法的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jifeng Zhang其他文献

Jifeng Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jifeng Zhang', 18)}}的其他基金

Novel methods to improve nuclease mediated homologous recombination, Administrative suppl
改进核酸酶介导的同源重组的新方法,行政补充
  • 批准号:
    10640401
  • 财政年份:
    2022
  • 资助金额:
    $ 54.38万
  • 项目类别:
BAF60c and abdominal aortic aneurysm
BAF60c 和腹主动脉瘤
  • 批准号:
    10474527
  • 财政年份:
    2021
  • 资助金额:
    $ 54.38万
  • 项目类别:
BAF60c and abdominal aortic aneurysm
BAF60c 和腹主动脉瘤
  • 批准号:
    10297104
  • 财政年份:
    2021
  • 资助金额:
    $ 54.38万
  • 项目类别:
Kruppel-like factor 11 (KLF11) and atherosclerosis
Kruppel 样因子 11 (KLF11) 和动脉粥样硬化
  • 批准号:
    9924279
  • 财政年份:
    2017
  • 资助金额:
    $ 54.38万
  • 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
  • 批准号:
    10615626
  • 财政年份:
    2017
  • 资助金额:
    $ 54.38万
  • 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改进核酸酶介导的同源重组的新方法
  • 批准号:
    9345608
  • 财政年份:
    2017
  • 资助金额:
    $ 54.38万
  • 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
  • 批准号:
    10383251
  • 财政年份:
    2017
  • 资助金额:
    $ 54.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了